Welcome to our dedicated page for Centessa Pharmaceuticals plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
Centessa Pharmaceuticals’ Chief Legal Officer, Iqbal J. Hussain, reported the automatic disposition of his equity in connection with Eli Lilly’s acquisition of Centessa. On June 24, 2026, all of his Ordinary Shares and share options, including 5,500 shares held indirectly by his spouse and 117,645 shares held directly, were transferred pursuant to a court-approved scheme of arrangement.
At the effective time, each Ordinary Share (and each ADS representing one Ordinary Share) became entitled to receive $38.00 in cash plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. His unvested RSUs, covering 98,025 Ordinary Shares, fully vested and, along with all outstanding options, were cancelled and converted into the same cash-and-CVR package rather than being exercised.
Centessa Pharmaceuticals plc Chief Technology & Quality Officer Tia L. Bush reported the automatic disposition of her equity in connection with Eli Lilly and Company’s acquisition of all outstanding Centessa ordinary shares. Bush’s 147,954 Ordinary Shares and all reported share options were transferred to the acquirer under a UK scheme of arrangement, leaving her with zero directly held shares and options after the transactions.
At the effective time of the scheme, holders of Ordinary Shares became entitled to receive $38.00 in cash per share, less applicable taxes, plus one non-transferable contingent value right (CVR) for each share. Each CVR provides for potential contingent payments of up to an aggregate of $9.00 per share, subject to specified milestones. The same per-share terms apply to American Depositary Shares, each representing one Ordinary Share. Unvested restricted share units fully vested and, along with share options, were cancelled and converted into the right to receive the cash consideration and one CVR per underlying Ordinary Share.
Centessa Pharmaceuticals plc Chief Financial Officer John J. Crowley reported dispositions of his equity in connection with the acquisition of Centessa by Eli Lilly and Company. On June 24, 2026, Eli Lilly, through a subsidiary, acquired all outstanding Centessa Ordinary Shares via a UK scheme of arrangement.
At the effective time, holders of Ordinary Shares became entitled to receive $38.00 in cash per Ordinary Share plus one contingent value right (CVR) for potential additional payments of up to $9.00 per Ordinary Share. The same terms applied per American Depositary Share.
Crowley disposed of 45,000 Ordinary Shares and had his Restricted Share Units and share options automatically cancelled and converted into rights to receive the cash consideration and one CVR per underlying share. The footnotes state these transfers occurred automatically under the Transaction Agreement, without any action or discretion by Crowley.
Centessa Pharmaceuticals’ Chief People Officer Karen M. Anderson reported the automatic disposition of all her equity in connection with Eli Lilly’s acquisition of the company. On the effective date of the UK court-approved scheme of arrangement, all her 62,085 Ordinary Shares transferred to Lilly.
Each Ordinary Share entitled the holder to receive $38.00 in cash plus a non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. Unvested RSUs covering 58,050 Ordinary Shares fully vested and were similarly cancelled for cash and CVRs.
All outstanding share options held by Anderson, including grants over 117,000, 120,000, 83,924, 28,336 and 75,000 Ordinary Shares at various exercise prices, were cancelled and converted into cash equal to the excess of the $38.00 cash consideration over each option’s exercise price, plus one CVR per underlying share. Following these transactions, she reported no remaining Ordinary Shares or options.
Centessa Pharmaceuticals' Chief Accounting Officer Raphael Deferiere reported the automatic disposition of his equity holdings in connection with Eli Lilly’s acquisition of the company. He disposed of 11,000 Ordinary Shares and options over 42,000 and 165,000 Ordinary Shares, leaving no remaining reported holdings.
Under a UK Scheme of Arrangement, Eli Lilly acquired all outstanding Centessa Ordinary Shares. At the effective time, holders became entitled to receive $38.00 in cash per Ordinary Share plus one contingent value right (CVR) for potential additional payments of up to $9.00 per share. RSUs and options were cancelled and converted into the right to receive the same cash and CVR-based consideration, and no discretionary trades were made by the reporting person.
Centessa Pharmaceuticals Chief Medical Officer Stephen Kanes reported the automatic disposition of his equity in connection with Eli Lilly’s acquisition of the company. He disposed of 120,000 Ordinary Shares and 500,000 share options to the issuer, leaving him with no reported holdings.
Under a UK Scheme of Arrangement, Eli Lilly, through a subsidiary, acquired all outstanding Centessa Ordinary Shares. At the effective time, each share became entitled to receive $38.00 in cash plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share.
Restricted Share Units and options held by Kanes were cancelled and converted into cash and CVRs in line with the transaction terms, with options paid in cash equal to the excess of the $38.00 cash consideration over the $16.90 per-share exercise price, plus one CVR for each underlying Ordinary Share.
Centessa Pharmaceuticals CEO Mario Alberto Accardi reported the automatic disposition of his equity in Centessa following its acquisition by Eli Lilly and Company. All 243,282 Ordinary Shares, which may be represented by ADSs, were transferred at the effective time of a court-approved Scheme of Arrangement.
Each Ordinary Share entitled the holder to receive $38.00 in cash plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. In addition, 81,806 Ordinary Shares underlying RSUs became fully vested and were converted into the same cash-and-CVR package.
All outstanding share options held by Accardi, across multiple grants with exercise prices ranging from $3.85 to $25.19, were automatically cancelled and converted into cash equal to the excess of the $38.00 cash consideration over each option’s exercise price, plus one CVR per underlying share. No shares or options were exercised before closing, and the filing shows zero Ordinary Shares and options remaining afterward.
Centessa Pharmaceuticals director Francesco De Rubertis reported indirect dispositions of Ordinary Shares in connection with Eli Lilly’s acquisition of the company. All reported holdings, held through various Medicxi investment funds, were automatically transferred at the effective time of a UK Scheme of Arrangement, leaving zero shares reported after the transactions. Under the deal, each Ordinary Share or ADS became entitled to receive $38.00 in cash per share plus one contingent value right, which can pay up to an additional $9.00 per share if specified milestones are achieved. The Form 4 notes that De Rubertis disclaims beneficial ownership of the Medicxi-held shares except for any pecuniary interest.
Centessa Pharmaceuticals plc director Mary Lynne Hedley reported the disposition to the issuer of multiple share option awards on June 24, 2026. The transactions reflect the closing of a deal in which Eli Lilly and Company, through a wholly owned subsidiary, acquired all outstanding Ordinary Shares of Centessa by a UK scheme of arrangement.
At the effective time of this scheme, each outstanding Centessa share option, whether vested or unvested, was automatically cancelled and converted into the right to receive cash plus a contingent value right. For each underlying Ordinary Share, holders became entitled to $38.00 in cash minus the option’s exercise price, and one non-transferable contingent value right that may pay up to an additional $9.00 per Ordinary Share if specified milestones are achieved. No share options were exercised before this effective time, and the filing shows Ms. Hedley’s covered options now have zero remaining balances.
Centessa Pharmaceuticals plc director Arjun Goyal reported automatic dispositions of his interests in the company in connection with its acquisition by Eli Lilly and Company. All outstanding Ordinary Shares were acquired through a UK court-approved scheme of arrangement.
At the effective time of the scheme, holders of Ordinary Shares became entitled to receive $38.00 in cash per share, plus one non-transferable contingent value right (CVR) that may pay up to an additional $9.00 per share if specified milestones are achieved. Goyal reported the transfer of 462,585 Ordinary Shares held indirectly through Vinyanshu Ventures LLC and the cancellation of several share option grants, which converted into cash-plus-CVR rights. The transfers and cancellations occurred automatically under the transaction agreement, and no options were exercised beforehand.